Serelaxin - Novartis
Alternative Names: ConXn; Reasanz; Recombinant human relaxin H2; Recombinant relaxin; Relaxin; Relaxin H2; rhRlx; RLX-030; RLX-030A; SUN-Y8002Latest Information Update: 27 Apr 2024
At a glance
- Originator Howard Florey Institute
- Developer Corthera; Genentech; Novartis
- Class Heart failure therapies; Peptide hormones
- Mechanism of Action Peptide hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute heart failure
- Discontinued Chronic heart failure; Coronary artery disease; Diffuse scleroderma; Female infertility; Fibrosis; Labour disorders; Labour induction; Liver cirrhosis; Peripheral arterial disorders; Portal hypertension; Preeclampsia; Pulmonary fibrosis; Pulmonary hypertension
Most Recent Events
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 08 Nov 2019 Efficacy and adverse event data from a phase II trial in Cirrhosis and Portal hypertension presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)
- 31 Aug 2018 University of Edinburgh completes the phase II STOPP trial in Cirrhosis and Portal hypertension in United Kingdom (IV) (NCT02669875)